Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International (BAX) reported Q4 2024 sales from continuing operations of $2.75 billion, up 1% reported and 2% on constant currency, exceeding guidance. Q4 U.S. GAAP diluted EPS loss was ($0.95), with adjusted EPS of $0.58 from continuing operations.
Full-year 2024 sales reached $10.64 billion, increasing 3% on both reported and constant currency basis. The company completed the sale of its Kidney Care business to Carlyle for approximately $3.4 billion in net after-tax proceeds, exceeding previous expectations of $3.15-3.25 billion.
For 2025 outlook, Baxter expects sales growth from continuing operations of 5-6% reported, and 4-5% operational. The company projects adjusted earnings from continuing operations of $2.45-2.55 per diluted share for full-year 2025.
Baxter International (NYSE:BAX) has announced its participation in the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The company's CFO, Joel Grade, will deliver a presentation at 1:10 p.m. Eastern Time. A live webcast will be available on Baxter's website, with replay access through September 1, 2025.
Baxter is a global medtech leader with over 90 years of experience, providing diagnostic, critical care, nutrition, hospital, and surgical products across various healthcare settings. The company's products and digital health solutions are available in more than 100 countries, serving millions of patients, caregivers, and healthcare providers daily. Baxter continues to build on its legacy of medical breakthroughs to develop innovative healthcare solutions.
Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the Raymond James & Associates' 46th Annual Institutional Investors Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Monday, March 3, 2025, at 1:05 p.m. Eastern Time.
Interested parties can access the live webcast of the presentation through www.baxter.com. The presentation recording will remain available for replay until August 30, 2025.
Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the upcoming Citi - 2025 Medtech & Life Sciences Access Day. Joel Grade, Baxter's chief financial officer, will deliver a presentation on Thursday, February 27, 2025, at 1:00 p.m. Eastern Time.
The presentation will be accessible through a live webcast on www.baxter.com. For those unable to attend the live session, a replay will remain available until Tuesday, August 26, 2025.
Baxter International (NYSE:BAX) has announced a quarterly cash dividend declaration by its Board of Directors. The company will pay $0.17 per share of common stock, with an indicated annual dividend rate of $0.68 per share. The dividend will be distributed on April 1, 2025, to stockholders of record as of February 28, 2025.
Baxter International (NYSE:BAX) announced the immediate retirement of José (Joe) E. Almeida from his positions as Chair, President, and CEO. Lead Independent Director Brent Shafer has been appointed as Chair and Interim CEO, with the board initiating a comprehensive search for a permanent CEO.
The company also appointed Heather Knight as Executive Vice President and Chief Operating Officer, responsible for global operations including sales, marketing, R&D, supply chain, and medical affairs. Nancy Schlichting will assume the role of lead independent director.
Baxter recently completed the sale of its Kidney Care business to Carlyle on January 31, 2025. The company expects Q4 and full-year 2024 results to align with previous guidance, maintaining its 2025 objectives of 4-5% operational sales growth and approximately 16.5% adjusted operating margin. However, these projections don't include potential impacts from recently announced U.S. tariffs on imports from Mexico, Canada, and China.
Baxter International (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. Investors can pre-register for the call through a provided registration link. The conference call will also be accessible via webcast through Baxter's website. The company notes that the call will be recorded and is copyrighted material, requiring Baxter's permission for any recording or rebroadcasting.
Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's chair, president and chief executive officer, José (Joe) E. Almeida, will deliver a presentation on Monday, January 13, 2025, at 10:30 a.m. Pacific Time. Interested parties can access the live webcast through www.baxter.com, with replay availability extending until July 12, 2025.
Baxter International (NYSE:BAX) announced five new injectable pharmaceutical product launches in the U.S., bringing their total launches to 10 in 2024. The new products include: Micafungin for Candida infections, Cyclophosphamide Injection for malignant diseases, Pantoprazole Sodium for GERD treatment, Cefazolin in a new 3g/150mL strength for various infections, and Levetiracetam for seizure treatment.
These ready-to-use formats utilize Baxter's proprietary container technology and are designed to improve operational efficiencies, simplify medication preparation, and enhance patient safety by reducing contamination risks and potential compounding errors.
Baxter International (NYSE:BAX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Thursday, December 5, 2024, at 9:10 a.m. Eastern Time. The presentation will be accessible via live webcast on www.baxter.com and will remain available for replay until Tuesday, June 3, 2025.
FAQ
What is the current stock price of Baxter Intl (BAX)?
What is the market cap of Baxter Intl (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
